The Therapeutic Significance of HER3 in Non-small Cell Lung Cancer (NSCLC): A Review Study

被引：6
作者：
Trinder, Amelia [1 ]
Ding, Ke [2 ]
Zhang, Jinwei [1 ,2 ]
机构：
[1] Univ Exeter, Inst Biomed & Clin Sci, Fac Hlth & Life Sci, Med Sch,Hatherly Labs, Streatham Campus, Exeter EX4 4PS, England
[2] Chinese Acad Sci, Shanghai Inst Organ Chem, Res Ctr Chem Kin, State Key Lab Chem Biol, 345 Lingling Rd, Shanghai 200032, Peoples R China
来源：
CURRENT MEDICINAL CHEMISTRY | 2025年 / 32卷 / 03期
关键词：
HER3; non-small cell lung cancer; monoclonal antibody; tyrosine kinase inhibitor; therapeutics; clinical trials; ANTI-HER3; MONOCLONAL-ANTIBODY; DRUG CONJUGATE; PHASE-I; EGFR; RESISTANCE; GROWTH; RECEPTOR; MUTATIONS; BLOCKADE; TUMORS;
D O I：
10.2174/0109298673269305231115102542
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
HER3 (Human Epidermal Growth Factor Receptor 3) is frequently overexpressed in various cancers, including non-small cell lung cancer (NSCLC), with a prevalence of 83% in primary tumors. Its involvement in tumorigenesis and resistance to targeted therapies makes HER3 a promising target for cancer treatment. Despite being initially considered "undruggable" due to its lack of catalytic activity, significant progress has been made in the development of anti-HER3 therapeutics. Monoclonal antibodies such as lumretuzumab, seribantumab, and patritumab have shown potential in targeting HER3 to overcome resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). Additionally, antibody-drug conjugates (ADCs) like HER3-DXd (patritumab deruxtecan) are new drug candidates that have demonstrated selective delivery of cytotoxic chemicals to NSCLC cells by exploiting HER3's widespread expression, minimizing cytotoxicity. This review aims to evaluate the efficacy of current HER3 therapeutics in development and their therapeutic potential in NSCLC, incorporating evidence from clinical trials.
引用
收藏
页码：434 / 446
页数：13
相关论文
共 76 条
[61]   Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer [J].
Sequist, Lecia, V ;
Gray, Jhanelle Elaine ;
Harb, Wael A. ;
Lopez-Chavez, Ariel ;
Doebele, Robert C. ;
Modiano, Manuel R. ;
Jackman, David Michael ;
Baggstrom, Maria Quintos ;
Atmaca, Akin ;
Felip, Enriqueta ;
Provencio, Mariano ;
Cobo, Manuel ;
Adiwijaya, Bambang ;
Kuesters, Geoffrey ;
Kamoun, Walid S. ;
Andreas, Karen ;
Pipas, J. Marc ;
Santillana, Sergio ;
Cho, Byoung Chul ;
Park, Keunchil ;
Shepherd, Frances A. .
ONCOLOGIST, 2019, 24 (08) :1095-1102
[62]   Epidermal growth factor receptor mutations in lung cancer [J].
Sharma, Sreenath V. ;
Bell, Daphne W. ;
Settleman, Jeffrey ;
Haber, Daniel A. .
NATURE REVIEWS CANCER, 2007, 7 (03) :169-181
[63]   Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549 [J].
Sithanandam, G ;
Fornwald, LW ;
Fields, J ;
Anderson, LM .
ONCOGENE, 2005, 24 (11) :1847-1859
[64]  
Steuer CE, 2022, J CLIN ONCOL, V40
[65]   Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review [J].
Stewart, Erin L. ;
Tan, Samuel Zhixing ;
Liu, Geoffrey ;
Tsao, Ming-Sound .
TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (01) :67-81
[66]   Third generation EGFR TKIs: current data and future directions [J].
Tan, Chee-Seng ;
Kumarakulasinghe, Nesaretnam Barr ;
Huang, Yi-Qing ;
Ang, Yvonne Li En ;
Choo, Joan Rou-En ;
Goh, Boon-Cher ;
Soo, Ross A. .
MOLECULAR CANCER, 2018, 17
[67]   Fully human anti-HER3 mAb U3-1287 (AMG 888) demonstrates unique in vitro and in vivo activities versus other HER family inhibitors in NSCLC models [J].
Treder, M. ;
Ogbagabriel, S. ;
Moor, R. ;
Schulze-Horsel, U. ;
Hettmann, T. ;
Rothe, M. ;
Radinsky, R. ;
Freeman, D. .
EJC SUPPLEMENTS, 2008, 6 (12) :99-99
[68]   Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors [J].
Wakui, Hiroshi ;
Yamamoto, Noboru ;
Nakamichi, Shinji ;
Tamura, Yousuke ;
Nokihara, Hiroshi ;
Yamada, Yasuhide ;
Tamura, Tomohide .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (03) :511-516
[69]   Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients [J].
Yang, Zhe ;
Yang, Nong ;
Ou, Qiuxiang ;
Xiang, Yi ;
Jiang, Tao ;
Wu, Xue ;
Bao, Hua ;
Tong, Xiaoling ;
Wang, Xiaonan ;
Shao, Yang W. ;
Liu, Yunpeng ;
Wang, Yan ;
Zhou, Caicun .
CLINICAL CANCER RESEARCH, 2018, 24 (13) :3097-3107
[70]   Untangling the ErbB signalling network [J].
Yarden, Y ;
Sliwkowski, MX .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2001, 2 (02) :127-137
12345678